DR REDDYS LABORATORIES Financial Statement Analysis
|
||
|
The Revenues of DR REDDYS LABORATORIES have increased by 16.54% YoY .
The Earnings Per Share (EPS) of DR REDDYS LABORATORIES has decreased by -25.90 % YoY. |
||
DR REDDYS LABORATORIES Last 5 Annual Financial Results
[BOM: 500124|NSE : DRREDDY]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹32,644 Cr | ₹28,011 Cr | ₹24,670 Cr | ₹21,545 Cr | ₹19,048 Cr |
| Expenses | ₹24,097 Cr | ₹20,078 Cr | ₹18,321 Cr | ₹17,778 Cr | ₹15,178 Cr |
| Operating Profit (Excl OI) | ₹8,547 Cr | ₹7,933 Cr | ₹6,349 Cr | ₹3,767 Cr | ₹3,870 Cr |
| Other Income | ₹1,097 Cr | ₹894 Cr | ₹1,056 Cr | ₹485 Cr | ₹291 Cr |
| Interest | ₹283 Cr | ₹171 Cr | ₹143 Cr | ₹96 Cr | ₹97 Cr |
| Depreciation | ₹1,704 Cr | ₹1,470 Cr | ₹1,250 Cr | ₹1,165 Cr | ₹1,229 Cr |
| Profit Before Tax | ₹7,680 Cr | ₹7,201 Cr | ₹6,049 Cr | ₹3,061 Cr | ₹2,884 Cr |
| Profit After Tax | ₹5,725 Cr | ₹5,578 Cr | ₹4,507 Cr | ₹2,183 Cr | ₹1,952 Cr |
| Consolidated Net Profit | ₹5,655 Cr | ₹5,578 Cr | ₹4,507 Cr | ₹2,183 Cr | ₹1,952 Cr |
| Earnings Per Share (Rs) | ₹50.25 | ₹67.81 | ₹334.41 | ₹270.55 | ₹131.16 |
| PAT Margin (%) | 12.34 | 17.54 | 19.91 | 18.27 | 10.13 |
| ROE(%) | 11.69 | 18.61 | 21.76 | 21.36 | 11.93 |
| ROCE(%) | 13.75 | 23.25 | 26.86 | 26.22 | 14.59 |
| Total Debt/Equity(x) | 0.20 | 0.14 | 0.07 | 0.06 | 0.18 |
Key Financials |
||
| Market Cap | : | ₹ 96,207.5 Cr |
| Revenue (TTM) | : | ₹ 33,227.9 Cr |
| Net Profit(TTM) | : | ₹ 3,169.3 Cr |
| EPS (TTM) | : | ₹ 38.0 |
| P/E (TTM) | : | 30.4 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| DR REDDYS LABORATORIES | -5.8% | -13.2% | -7.7% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.8% | 3.5% | 14.7% |
| DIVIS LABORATORIES | -1% | 7.3% | 7.6% |
| TORRENT PHARMACEUTICALS | -0.9% | 10.1% | 44.6% |
| CIPLA | -2.1% | -1.8% | -6% |
| MANKIND PHARMA | -2.4% | 1.2% | -3.2% |
| LUPIN | -4.4% | 0.1% | 22.5% |
| ZYDUS LIFESCIENCES | -3.3% | 0.9% | 13.4% |
| AUROBINDO PHARMA | -1.9% | 0.1% | 32.1% |
DR REDDYS LABORATORIES Revenues
[BOM: 500124|NSE : DRREDDY]
| Y-o-Y | 16.54 % |
| 5 Yr CAGR | 14.42 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹32,644 Cr | 16.54 | |
| Mar2025 | ₹28,011 Cr | 13.54 | |
| Mar2024 | ₹24,670 Cr | 14.50 | |
| Mar2023 | ₹21,545 Cr | 13.11 | |
| Mar2022 | ₹19,048 Cr | - | |
DR REDDYS LABORATORIES Operating Profit
[BOM: 500124|NSE : DRREDDY]
| Y-o-Y | 7.74 % |
| 5 Yr CAGR | 21.91 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹8,547 Cr | 7.74 | |
| Mar2025 | ₹7,933 Cr | 24.95 | |
| Mar2024 | ₹6,349 Cr | 68.52 | |
| Mar2023 | ₹3,767 Cr | -2.65 | |
| Mar2022 | ₹3,870 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -7.56 % |
| 5 Yr CAGR | 6.54 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 26.18% | -7.56 | |
| Mar2025 | 28.32% | 10.02 | |
| Mar2024 | 25.74% | 47.17 | |
| Mar2023 | 17.49% | -13.93 | |
| Mar2022 | 20.32% | - | |
DR REDDYS LABORATORIES Profit After Tax
[BOM: 500124|NSE : DRREDDY]
| Y-o-Y | 1.38 % |
| 5 Yr CAGR | 30.47 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹5,655 Cr | 1.38 | |
| Mar2025 | ₹5,578 Cr | 23.75 | |
| Mar2024 | ₹4,507 Cr | 106.52 | |
| Mar2023 | ₹2,183 Cr | 11.83 | |
| Mar2022 | ₹1,952 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -29.65 % |
| 5 Yr CAGR | 5.06 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 12.34 % | -29.65 | |
| Mar2025 | 17.54 % | -11.90 | |
| Mar2024 | 19.91 % | 8.98 | |
| Mar2023 | 18.27 % | 80.36 | |
| Mar2022 | 10.13 % | - | |
DR REDDYS LABORATORIES Earnings Per Share (EPS)
[BOM: 500124|NSE : DRREDDY]
| Y-o-Y | -25.90 % |
| 5 Yr CAGR | -21.33 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹50 | -25.90 | |
| Mar2025 | ₹68 | -79.72 | |
| Mar2024 | ₹334 | 23.60 | |
| Mar2023 | ₹271 | 106.27 | |
| Mar2022 | ₹131 | - | |
DR REDDYS LABORATORIES Return on Capital Employed (ROCE)
[BOM: 500124|NSE : DRREDDY]
| Y-o-Y | -40.86 % |
| 5 Yr CAGR | -1.47 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 13.75% | -40.86 | |
| Mar2025 | 23.25% | -13.44 | |
| Mar2024 | 26.86% | 2.44 | |
| Mar2023 | 26.22% | 79.71 | |
| Mar2022 | 14.59% | - | |
DR REDDYS LABORATORIES Share Price vs Sensex
| Current Share Price | : | ₹1,152.6 |
| Current MarketCap | : | ₹ 96,207.5 Cr |
| Updated EOD on | : | Jul 24,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DR REDDYS LABORATORIES | -5.8% |
-13.2% |
-7.7% |
| SENSEX | -2.7% |
-0.2% |
-8% |
DR REDDYS LABORATORIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE DIVIDEND STABILITY INDEX | -0.1% | 0.4% | 2.5% |
| BSE SENSEX NEXT 30 | -0.2% | -0.2% | 6.1% |
| BSE INDIA MANUFACTURING INDEX | -0.3% | -0.8% | 3.1% |
| BSE LOW VOLATILITY INDEX | -0.7% | 0.5% | -4.6% |
| BSE HEALTHCARE | -0.8% | 1.8% | 9.1% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY ALPHA QUALITY VALUE LOW-VOLATILITY 30 | 0.4% | 1.3% | -2.8% |
| NIFTY ALPHA QUALITY LOW-VOLATILITY 30 | 0.2% | 1.3% | 1.2% |
| NIFTY500 LOW VOLATILITY 50 INDEX | 0.1% | 1.6% | 1.6% |
| NIFTY QUALITY LOW-VOLATILITY 30 | 0% | 2.1% | -4.1% |
| NIFTY100 QUALITY 30 | -0.1% | 1.6% | -2.2% |
You may also like the below Video Courses
FAQ about DR REDDYS LABORATORIES Financials
How the annual revenues of DR REDDYS LABORATORIES have changed ?
The Revenues of DR REDDYS LABORATORIES have increased by 16.54% YoY .
How the Earnings per Share (EPS) of DR REDDYS LABORATORIES have changed?
The Earnings Per Share (EPS) of DR REDDYS LABORATORIES has decreased by -25.90 % YoY .
Check out Intrinsic Value of Peers of DR REDDYS LABORATORIES
Compare Stock Analytics of Peers of DR REDDYS LABORATORIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
